- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05432804
Testowanie dodania leku przeciwnowotworowego, selinexoru, do zwykłej chemioterapii (temozolomid) guzów mózgu, które powróciły po poprzednim leczeniu
Faza 1/2 badania selineksoru i temozolomidu w nawracającym glejaku wielopostaciowym
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.
Przegląd badań
Status
Warunki
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as determined by dose-limiting toxicities (DLTs) and the total toxicity profile. (Phase I) II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by progression-free survival (PFS). (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate overall response rate as determined by Response Assessment in Neuro-Oncology (RANO) response criteria.
II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by 6-month PFS (6mPFS) and overall survival (OS).
III. To validate signatures of vulnerability to predict response to selinexor through ribonucleic acid (RNA) sequencing for 6 top-scoring gene pairs, whole exome sequencing, P53, EGFR, and Mcl-1.
OUTLINE: This is a phase I, dose-escalation study of selinexor in combination with fixed dose temozolomide followed by a phase II study that compares selinexor temozolomide combination therapy vs. temozolomide monotherapy. Patients are randomized to 1 of 2 groups for the phase II part of this trial.
GROUP I (Phase II): Patients receive temozolomide orally (PO) once daily (QD) on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
GROUP II (Phase I and II): Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Phase I completed as of April 2024)
Patients undergo magnetic resonance imaging (MRI) throughout the study and blood sample collection while on study.
After completion of study treatment, patients are followed up every 2 months up to 2 years.
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85054
- Rekrutacyjny
- Mayo Clinic Hospital in Arizona
-
Kontakt:
- Alyx B. Porter Umphrey
- Numer telefonu: 507-538-7623
- E-mail: porter.alyx@mayo.edu
-
Główny śledczy:
- Alyx B. Porter Umphrey
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- Rekrutacyjny
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-826-4673
- E-mail: becomingapatient@coh.org
-
Główny śledczy:
- Jana L. Portnow
-
Irvine, California, Stany Zjednoczone, 92612
- Rekrutacyjny
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Główny śledczy:
- Frances E. Chow
-
La Jolla, California, Stany Zjednoczone, 92093
- Rekrutacyjny
- UC San Diego Moores Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Główny śledczy:
- David E. Piccioni
-
Los Angeles, California, Stany Zjednoczone, 90033
- Rekrutacyjny
- USC / Norris Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 323-865-0451
-
Główny śledczy:
- Jacob S. Thomas
-
Los Angeles, California, Stany Zjednoczone, 90020
- Rekrutacyjny
- Keck Medicine of USC Koreatown
-
Kontakt:
- Site Public Contact
- Numer telefonu: 213-388-0908
-
Główny śledczy:
- Jacob S. Thomas
-
Los Angeles, California, Stany Zjednoczone, 90033
- Rekrutacyjny
- Los Angeles General Medical Center
-
Główny śledczy:
- Jacob S. Thomas
-
Kontakt:
- Site Public Contact
- Numer telefonu: 323-865-0451
- E-mail: uscnorrisinfo@med.usc.edu
-
Orange, California, Stany Zjednoczone, 92868
- Rekrutacyjny
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Główny śledczy:
- Frances E. Chow
-
Sacramento, California, Stany Zjednoczone, 95817
- Rekrutacyjny
- University of California Davis Comprehensive Cancer Center
-
Główny śledczy:
- Orwa Aboud
-
Kontakt:
- Site Public Contact
- Numer telefonu: 916-734-3089
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- UCHealth University of Colorado Hospital
-
Kontakt:
- Site Public Contact
- Numer telefonu: 720-848-0650
-
Główny śledczy:
- Denise M. Damek
-
-
Florida
-
Coral Gables, Florida, Stany Zjednoczone, 33146
- Rekrutacyjny
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Kontakt:
- Site Public Contact
- Numer telefonu: 305-243-2647
-
Główny śledczy:
- Macarena I. De La Fuente
-
Deerfield Beach, Florida, Stany Zjednoczone, 33442
- Rekrutacyjny
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Kontakt:
- Site Public Contact
- Numer telefonu: 305-243-2647
-
Główny śledczy:
- Macarena I. De La Fuente
-
Jacksonville, Florida, Stany Zjednoczone, 32224-9980
- Rekrutacyjny
- Mayo Clinic in Florida
-
Kontakt:
- Site Public Contact
- Numer telefonu: 855-776-0015
-
Główny śledczy:
- Sani H. Kizilbash
-
Miami, Florida, Stany Zjednoczone, 33136
- Rekrutacyjny
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 305-243-2647
-
Główny śledczy:
- Macarena I. De La Fuente
-
Tampa, Florida, Stany Zjednoczone, 33612
- Rekrutacyjny
- Moffitt Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Główny śledczy:
- Patrick T. Grogan
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Rekrutacyjny
- Emory University Hospital/Winship Cancer Institute
-
Główny śledczy:
- Kimberly Hoang
-
Kontakt:
- Site Public Contact
- Numer telefonu: 404-778-1868
-
Atlanta, Georgia, Stany Zjednoczone, 30308
- Rekrutacyjny
- Emory University Hospital Midtown
-
Główny śledczy:
- Kimberly Hoang
-
Kontakt:
- Site Public Contact
- Numer telefonu: 888-946-7447
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Główny śledczy:
- Lauren Singer
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- Rekrutacyjny
- University of Chicago Medicine-Orland Park
-
Kontakt:
- Site Public Contact
- Numer telefonu: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Główny śledczy:
- Lauren Singer
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- Rekrutacyjny
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 859-257-3379
-
Główny śledczy:
- John L. Villano
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Rekrutacyjny
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Numer telefonu: 855-776-0015
-
Główny śledczy:
- Sani H. Kizilbash
-
-
New Jersey
-
Livingston, New Jersey, Stany Zjednoczone, 07039
- Rekrutacyjny
- Cooperman Barnabas Medical Center
-
Główny śledczy:
- Andrew B. Brown
-
Kontakt:
- Site Public Contact
- Numer telefonu: 973-322-5200
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rekrutacyjny
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-235-7356
-
Główny śledczy:
- Andrew B. Brown
-
Newark, New Jersey, Stany Zjednoczone, 07101
- Rekrutacyjny
- Rutgers New Jersey Medical School
-
Kontakt:
- Site Public Contact
- Numer telefonu: 732-235-7356
-
Główny śledczy:
- Andrew B. Brown
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Aktywny, nie rekrutujący
- Roswell Park Cancer Institute
-
New York, New York, Stany Zjednoczone, 10032
- Rekrutacyjny
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
Główny śledczy:
- Peter C. Pan
-
New York, New York, Stany Zjednoczone, 10016
- Rekrutacyjny
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Kontakt:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
Główny śledczy:
- Jose R. McFaline Figueroa
-
The Bronx, New York, Stany Zjednoczone, 10461
- Rekrutacyjny
- Montefiore Medical Center-Einstein Campus
-
Kontakt:
- Site Public Contact
- Numer telefonu: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Główny śledczy:
- Adilia M. Hormigo
-
-
North Carolina
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Rekrutacyjny
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Numer telefonu: 336-713-6771
-
Główny śledczy:
- Roy E. Strowd
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- Rekrutacyjny
- University of Cincinnati Cancer Center-UC Medical Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 513-584-7698
- E-mail: cancer@uchealth.com
-
Główny śledczy:
- Lalanthica V. Yogendran
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Rekrutacyjny
- Cleveland Clinic Foundation
-
Główny śledczy:
- David M. Peereboom
-
Kontakt:
- Site Public Contact
- Numer telefonu: 866-223-8100
- E-mail: TaussigResearch@ccf.org
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Rekrutacyjny
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Główny śledczy:
- Pierre Giglio
-
West Chester, Ohio, Stany Zjednoczone, 45069
- Rekrutacyjny
- University of Cincinnati Cancer Center-West Chester
-
Kontakt:
- Site Public Contact
- Numer telefonu: 513-584-7698
- E-mail: cancer@uchealth.com
-
Główny śledczy:
- Lalanthica V. Yogendran
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- Rekrutacyjny
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Główny śledczy:
- James D. Battiste
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- Rekrutacyjny
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Numer telefonu: 412-647-8073
-
Główny śledczy:
- Megan Mantica
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Zawieszony
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- Aktywny, nie rekrutujący
- University of Virginia Cancer Center
-
Richmond, Virginia, Stany Zjednoczone, 23298
- Aktywny, nie rekrutujący
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- Rekrutacyjny
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Główny śledczy:
- Ankush Bhatia
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Stany Zjednoczone, 53718
- Rekrutacyjny
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Główny śledczy:
- Ankush Bhatia
-
Kontakt:
- Site Public Contact
- Numer telefonu: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients must have histologically confirmed glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or biopsy upon first recurrence. Recurrence at site of prior involvement is defined by histopathological evidence of viable neoplastic cells associated with any of the following: mitotic activity, increased proliferation rate, micro-endothelial proliferation, or pseudo-palisading necrosis
- Prior to resection or biopsy, patients must have measurable disease, defined as at least one bi-dimensional contrast-enhancing lesion with clearly defined margins, with 2 perpendicular diameters of at least 10 mm, visible on >= 2 axial slices
- Patients must have received first-line treatment of temozolomide plus radiotherapy
- Patients must not have received any prior therapy aside from resection or biopsy for their recurrent disease
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of selinexor (KPT-330) in combination with temozolomide in patients < 18 years of age, children are excluded from this study
- Karnofsky performance status >= 60% (Eastern Cooperative Oncology Group [ECOG] =< 2)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 10 g/dL
- Total bilirubin =< 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 3 x institutional ULN
- Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- The effects of selinexor (KPT-330) and temozolomide on the developing human fetus are unknown. For this reason and because selective nuclear export inhibitors as well as deoxyribonucleic acid (DNA) alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 180 days after the last dose of temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of study treatment administration
- Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients who have had chemotherapy must have full recovery of organ and marrow function following the nadir of the last chemotherapy cycle
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- Patients who have previously received bevacizumab
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide
- History of hypersensitivity to dacarbazine (DTIC), since both dacarbazine and temozolomide are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC)
- Patients with uncontrolled intercurrent illness
- Pregnant women are excluded from this study because selinexor (KPT-330) is a selective inhibitor of nuclear export with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selinexor (KPT-330), breastfeeding is not allowed for mothers during treatment with selinexor (KPT-330) and for 7 days after the last dose. These potential risks may also apply to other agents used in this study
- Hospitalized patients with severe coronavirus disease of 2019 (COVID-19) who are >= 75 years old, or with a high-risk COVID-GRAM score, or with lactate dehydrogenase (LDH) > 370 (U/L) AND D-Dimer > 600 mcg/L FEU should not receive low-dose selinexor (KPT-330) pending additional results
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Group I (temozolomide)
Patients receive temozolomide PO QD on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Given PO
Inne nazwy:
Given PO |
|
Eksperymentalny: Group II (temozolomide, selinexor)
Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study. |
Undergo blood sample collection
Inne nazwy:
Undergo MRI
Inne nazwy:
Given PO
Inne nazwy:
Given PO
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Recommended phase 2 dose (RP2D) (Phase I)
Ramy czasowe: Up to 28 days
|
Any eligible patient who receives at least one dose of protocol-defined therapy will be considered evaluable for dose-limiting toxicity (DLT) if either of the following occurs: (1) the patient experiences a DLT during cycle 1 of therapy; or (2) the patient receives at least 4 doses of temozolomide and 1 dose of selinexor. All other patients enrolled during the phase 1 portion of the study will be considered inevaluable for DLT and may be replaced for the purposes of establishing the RP2D. |
Up to 28 days
|
|
Progression-free survival (PFS) (Phase II)
Ramy czasowe: From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years
|
Patients who experience disease progression or death will be considered to have experienced a PFS-event; otherwise the patient is considered censored at last contact. |
From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Response according to response assessment in neuro-oncology criteria (RANO) criteria
Ramy czasowe: Up to 3 years
|
A patient who is evaluated as complete response, partial response, or stable disease will be considered a RANO-responder. All other patients will be considered RANO-non-responders. Response rate will be calculated and comparisons made using categorical data methods. |
Up to 3 years
|
|
Six-month progression-free survival (PFS-6)
Ramy czasowe: At 6 months
|
Any patient considered evaluable for RANO response will be considered evaluable for PFS-6. Any evaluable patient who is considered progression free for the primary analysis will be considered a PFS-6 responder. All other evaluable patients will be considered PFS-6 non-responders. |
At 6 months
|
|
Median overall survival
Ramy czasowe: Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years
|
Will be calculated from the Kaplan-Meier estimate of the probability of death as a function of time since enrollment. Ninety-five percent (95%) confidence intervals will be calculated as well. |
Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years
|
|
Molecular signatures of vulnerability
Ramy czasowe: Up to 3 years
|
Will be assessed using logistic regression for the outcome measure (RANO response) and using proportional hazard regression with the biological characteristic of interest as the predictor variable for risk for PFS event. Patients considered evaluable for RANO response and PFS, respectively, will contribute to the analyses for these exploratory outcomes. Two-sided statistical testing will be employed, and a p-value of 0.05 or less will be considered as indicating significant evidence of association between the particular signature and the outcome of interest. |
Up to 3 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Jana L Portnow, City of Hope Comprehensive Cancer Center LAO
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Gwiaździak
- Glejak
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Glejaka wielopostaciowego
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Azole
- Dacarbazine
- Triazennes
- Imidazoles
- Techniki chemii, analityczne
- Analiza widma
- Temozolomid
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Selinexor
Inne numery identyfikacyjne badania
- NCI-2022-05066
- UM1CA186717 (Grant/umowa NIH USA)
- NCI-2022-05066 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- 10505 (Inny identyfikator: CTEP)
- PHII-222
- 10505 (Inny identyfikator: City of Hope Comprehensive Cancer Center LAO)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .